Stay updated on Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi
Sign up to get notified when there's something new on the Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi page.

Latest updates to the Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe Taiwan site entry was updated from Taoyuan District, Taiwan, 333 to Taoyuan, Taiwan, 333, aligning the location with city-level nomenclature.SummaryDifference0.0%

- Check15 days agoChange DetectedThe page’s displayed update/version information was refreshed, adjusting the revision number and associated date markers. This reflects a site record update or posting/version maintenance rather than substantive changes to the clinical study information.SummaryDifference0.1%

- Check23 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check37 days agoChange DetectedPadua, Italy (35128) has been replaced with Padova, Italy (35128) for the Italy site entry.SummaryDifference0.0%

- Check52 days agoChange DetectedSite revision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check66 days agoChange DetectedPublication entry updated to reflect a full 2026 Clin Lung Cancer article by the SAVANNAH study authors with a DOI. The previous 'Online ahead of print' citation was removed.SummaryDifference0.1%

Stay in the know with updates to Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi
Enter your email address, and we'll notify you when there's something new on the Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi page.